Articles dans des revues avec comité de lecture (182)
  1. 58. Bielen, R., De Galocsy, C., Janssens, F., Van Overbeke, L., van Steenkiste, C., D'Heygere, F., Cool, M. M., Wuyckens, K., Nevens, F., Robaeys, G., Moreno, C., Van Vlierberghe, H., Bourgeois, S., Mulkay, J.-P., Vanwolleghem, T., Verlinden, W., Brixco, C., & Decaestecker, J. (2017). The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. Journal of viral hepatitis, 24(11), 976-981. doi:10.1111/jvh.12726
  2. 59. Dharancy, S., Moreno, C., Conti, F., Dumortier, J., Di Martino, V., Radenne, S., De Ledinghen, V., D'Alteroche, L., Silvain, C., Besch, C., Perre, P., Coilly, A., Botta-Fridlund, D., Francoz, C., Habersetzer, F., Montialoux, H., Abergel, A., Debette-Gratien, M., Rohel, A., Rossignol, E., Samuel, D., Duclos-Vallée, J.-C., Fougerou-Leurent, C., Pageaux, G.-P., Duvoux, C., Kamar, N., Leroy, V., Tran, A., Houssel-Debry, P., & Canva, V. (2017). Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. American Journal of Transplantation, 17(11), 2869-2878. doi:10.1111/ajt.14490
  3. 60. Gustot, T., Fernández, J. J., Szabo, G., Albillos, A., Louvet, A., Jalan, R., Moreau, R., & Moreno, C. (2017). Sepsis in alcohol-related liver disease. Journal of hepatology, 67(5), 1031-1050. doi:10.1016/j.jhep.2017.06.013
  4. 61. Marot, A., Henrion, J., Knebel, J. F., Moreno, C., & Deltenre, P. (2017). Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: An observational study. PloS one, 12(10), e0186715. doi:10.1371/journal.pone.0186715
  5. 62. Gane, E., Moreno, C., Colombo, M., Yoshida, E. E., Nelson, D., Collins, C., Lei, Y., Kosloski, M., Mensa, F. F., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., & Persico, M. (2017). Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. The New England journal of medicine, 377(15), 1448-1455. doi:10.1056/NEJMoa1704053
  6. 63. Litwak, S. A., Pang, L., Galic, S., Igoillo Esteve, M., Stanley, W. J., Turatsinze, J. V., Loh, K., Thomas, H. H., Sharma, A., Trepo, E., Moreno, C., Gough, D. J., Eizirik, D., de Haan, J. B., & Gurzov, E. N. (2017). JNK Activation of BIM Promotes Hepatic Oxidative Stress, Steatosis and Insulin Resistance in Obesity. Diabetes (New York, N.Y.). doi:10.2337/db17-0348
  7. 64. Bielen, R., De Galocsy, C., Janssens, F., Cool, M. M., Van Overbeke, L., van Steenkiste, C., D'Heygere, F., Cools, W., Nevens, F., Robaeys, G., Moreno, C., Van Vlierberghe, H., Bourgeois, S., Mulkay, J.-P., Vanwolleghem, T., Verlinden, W., Brixko, C., & Decaestecker, J. (2017). Belgian experience with direct acting antivirals in people who inject drugs. Drug and alcohol dependence, 177, 214-220. doi:10.1016/j.drugalcdep.2017.04.003
  8. 65. Marot, A., Trepo, E., Doerig, C., Schoepfer, A. A., Moreno, C., & Deltenre, P. (2017). Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver international, 37(5), 707-716. doi:10.1111/liv.13318
  9. 66. Sulkowski, M., Matthews, G., Molina, J.-M., Moreno, C., Pineda, J. A., Pulido, F., Rivero, A., Rockstroh, J., Hernandez, D., McPhee, F., Eley, T., Fessel, W. J., Liu, Z., Mendez, P., Hughes, E., Noviello, S., Ackerman, P., Lazzarin, A., Berenguer, J., Zakharova, N., Cheinquer, H., Côté, P., Dieterich, D., & Gadano, A. (2017). Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Hepatology International, 11(2), 188-198. doi:10.1007/s12072-017-9788-z
  10. 67. Blach, S., & Moreno, C. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology and Hepatology, 2(3), 161-176. doi:10.1016/S2468-1253(16)30181-9
  11. 68. Bourgeois, S., Francque, S., Vijgen, L., Kakuda, T. T., Hoeben, E., Luo, D., Vandebosch, A., Jacquemyn, B., Van Remoortere, P., Verloes, R., Van Vlierberghe, H., Moreno, C., Orlent, H., Nevens, F., Arasteh, K., Horsmans, Y., Schattenberg, J. M., & Buggisch, P. (2017). Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC gastroenterology, 17(1), 26. doi:10.1186/s12876-017-0580-2
  12. 69. Degré, D., Vanwolleghem, T., Dastis, S. N., Gustot, T., Geerts, A., van Steenkiste, C., De Galocsy, C., Lepida, A., Orlent, H., Moreno, C., Serste, T., Lasser, L., Delwaide, J., Starkel, P., Laleman, W., Langlet, P., Reynaert, H., & Bourgeois, S. (2017). Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: A real-world experience from Belgium. PloS one, 12(1), e0170933. doi:10.1371/journal.pone.0170933
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Suivant >>